스미스 앤 네퓨(SNN) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

SNN

Smith & Nephew plc ADR

7월 27일 3:56 PM ET (한국 7/28 04:56)

$30.57

+0.80 ▲ +2.69%

스미스 앤 네퓨(SNN) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$12.9B

미드캡

P/E

21.3

적정 수준

배당수익률

2.68%

52주 위치

20%

저점 +7% · 고점 -21%

애널리스트

매수

C+

Fundamental health

vs. Medical Devices

수익성

Top 33%

성장

Top 44%

밸류에이션

Top 69%

재무 안정

Top 45%

Index ⓘ	-	P/E ⓘ	21.3	EPS (ttm) ⓘ	1.44	Insider Own ⓘ	0.06%	Shs Outstand ⓘ	424.7M	Perf Week ⓘ	-0.07%
Market Cap ⓘ	12.86B	Forward P/E ⓘ	12.42	EPS next Y ⓘ	11.25%	Insider Trans ⓘ	-	Shs Float ⓘ	420.4M	Perf Month ⓘ	1.02%
Enterprise Value ⓘ	15.63B	PEG ⓘ	1.19	EPS next Q ⓘ	-	Inst Own ⓘ	12.17%	Short Float ⓘ	0.89%	Perf Quarter ⓘ	-4.23%
Income ⓘ	0.63B	P/S ⓘ	2.08	EPS this Y ⓘ	8.48%	Inst Trans ⓘ	-14.85%	Short Ratio ⓘ	2.63	Perf Half Y ⓘ	-7.59%
Sales ⓘ	6.18B	P/B ⓘ	2.45	EPS next 5Y ⓘ	10.43%	ROA ⓘ	6.02%	Short Interest ⓘ	3.72M	Perf YTD ⓘ	-6.83%
Book/sh ⓘ	12.45	P/C ⓘ	23.08	EPS past 3/5Y ⓘ	41.4% 6.97%	ROE ⓘ	11.87%	52W High ⓘ	-21.19% ($38.79)	Perf Year ⓘ	-2.89%
Cash/sh ⓘ	1.32	P/FCF ⓘ	15.15	Sales past 3/5Y ⓘ	5.84% 6.1%	ROIC ⓘ	7.4%	52W Low ⓘ	7.06% ($28.56)	Perf 3Y ⓘ	-0.62%
Dividend Est. ⓘ	$0.82 (2.68%)	EV/EBITDA ⓘ	9.7	EPS Y/Y TTM ⓘ	52.96%	Gross Margin ⓘ	68.02%	Volatility(W/M) ⓘ	1.78% 1.91%	Perf 5Y ⓘ	-28.74%
Dividend TTM ⓘ	0.78	EV/Sales ⓘ	2.53	Sales Y/Y TTM ⓘ	6.3%	Oper. Margin ⓘ	16.78%	ATR (14) ⓘ	0.71	Perf 10Y ⓘ	-11.24%
Dividend Ex-Date ⓘ	2026/3/27	Quick Ratio ⓘ	1.25	EPS Q/Q ⓘ	69.56%	Profit Margin ⓘ	10.14%	RSI (14) ⓘ	51.98	Recom ⓘ	2.42
Dividend Gr. 3/5Y ⓘ	0.91% 0.54%	Current Ratio ⓘ	2.57	Sales Q/Q ⓘ	6.91%	SMA20 ⓘ	1.09% ($30.24)	Beta ⓘ	0.59	Target Price ⓘ	$35.68
Payout ⓘ	52.04%	Debt/Eq ⓘ	0.63	Earnings ⓘ	2026/3/2	SMA50 ⓘ	1.09% ($30.24)	Rel Volume ⓘ	0.86	Prev Close ⓘ	$29.77
Employees ⓘ	18362	LT Debt/Eq ⓘ	0.6	EPS/Sales Surpr. ⓘ	2.05% 15.48%	SMA200 ⓘ	-6.83% ($32.81)	Avg Volume(3M) ⓘ	1.41M	Price ⓘ	$30.57
IPO ⓘ	1999/11/16	Option/Short ⓘ	Yes/Yes			Trades ⓘ	8375	Volume ⓘ	1,216,505	Change ⓘ	2.69%

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Smith & Nephew plc ADR (SNN) Investment Analysis

What kind of company is Smith & Nephew plc ADR?

스미스 앤 네퓨(SNN) 방어주

Healthcare · Medical Devices

#806 by Market Cap — Mid-Cap

A global medical device company headquartered in the UK, specializing in orthopedic implants such as artificial joints, sports medicine devices, and wound care products, listed on the US market in ADR form.

Learn more about Smith & Nephew plc ADR →

Market Cap

$12.9B

Approx. KRW 17.6 trillion

⚖️ 4% of Samsung Electronics

Market Cap Rank806

Employees18,362people

IPO1999/11/16

Current Price$30.57 ≈ 41,881원

NYSE · United Kingdom

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🎯 Ex-div 2026년 3월 27일 (금)

🔔 Earnings release 2026년 3월 2일 (월) · 장 시작 전 EPS +2.0% 매출 +15.5%

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

16.8%

✓ 우수

My positionTop 25%

Low range Average High range

Medical Devices Median -23.9% · Top 9%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

10.1%

✓ 우수

My positionTop 25%

Low range Average High range

Medical Devices Median -34.5% · Top 15%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

68.0%

✓ 양호

My positionMid-range

Low range Average High range

Medical Devices Median 54.4% · Top 26%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

11.9%

✓ 양호

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 11.9% · Around average

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

6.0%

✓ 양호

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 5.1% · Top 45%

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

7.4%

✓ 양호

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 7.4% · Around average

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.63

✓ Average

My positionMid-range

Low range Average High range

Medical Devices Median 0.39

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

2.57

✓ 양호

My positionMid-range

Low range Average High range

Medical Devices Median 2.91

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

1.25

✓ 양호

My positionMid-range

Low range Average High range

Medical Devices Median 2.09

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$35.68

현재가 대비 +16.7%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

12.42배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

PEG (성장 반영 밸류)

1.19

적정

💡 PEG 1~1.5 — 성장 대비 합리적

내년 EPS 예상 성장률

+11.3%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+10.4%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability

Beat estimates in 1 of the last 1 quarters

예상 상회

예상 부합

예상 하회

100%

상회 비율

+2.0%

평균 서프라이즈

2026.03.02

상회

+2.0%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+8.5%

평균

My positionMid-range

Low range Average High range

방어주 대형주 Median 9.6% · Bottom 45%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+11.3%

양호

My positionMid-range

Low range Average High range

방어주 대형주 Median 10.8% · Top 48%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+10.4%

양호

My positionMid-range

Low range Average High range

방어주 대형주 Median 9.8% · Top 44%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+41.4%

우수

My positionTop 25%

Low range Average High range

방어주 대형주 Median 4.7% · Top 11%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+7.0%

양호

My positionMid-range

Low range Average High range

방어주 대형주 Median 4.1% · Top 36%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+6.1%

평균

My positionMid-range

Low range Average High range

방어주 대형주 Median 6.7% · Bottom 43%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+6.9%

평균

My positionMid-range

Low range Average High range

방어주 대형주 Median 8.4% · Bottom 43%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -97%p below the market

SNN -28.7% · S&P 500 +68.0%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-96.7%p

Significantly behind the market

vs Health Care (XLV)

-52.4%p

Significantly behind the sector average

1-year basis

vs S&P 500

-19.4%p

behind the market

vs Health Care (XLV)

-22.6%p

behind the sector average

Rank among peers

5-year return Lower-Mid (lower 42%) Based on 13 peers

1-year return Upper-Mid (35%) Based on 14 peers

Current position within 52-week range

Low (-7.1%p) High (-21.2%p)

Current price is 7.1% above the 52-week low and 21.2% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-22.1%

Annualized volatility

28.1%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-24

Uptrend zone

Current price $30.57 above the midline ($30.24). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-24

Neutral zone — weak trend

MACD 0.005 · Signal 0.021 · Hist -0.015. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-24

Bullish zone

RSI 52.0 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 51.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

21.30x

✓ Very cheap

My positionTop 25%

Low range Average High range

Medical Devices median 30.60x · Top 22% — relatively cheap within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

12.42x

✓ Very cheap

My positionTop 25%

Low range Average High range

Medical Devices median 17.57x · Top 23% — relatively cheap within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

2.45x

✓ Cheap

My positionMid-range

Low range Average High range

Medical Devices median 2.58x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

2.08x

✓ Cheap

My positionMid-range

Low range Average High range

Medical Devices median 2.64x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

9.70x

✓ Very cheap

My positionTop 25%

Low range Average High range

Medical Devices median 14.42x · Top 23% — relatively cheap within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

15.15x

✓ Cheap

My positionMid-range

Low range Average High range

Medical Devices median 21.45x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$35.68 vs. current price +16.7%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Medical Devices

Who owns it?

Ownership flow shows some pressure

Institutional net selling -14.8% · Short interest light 0.9%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

-14.8%

Institutions large net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 12.2%

Retail-led

Healthcare 대형주 Median 91.9%

🧑‍💼 Insiders 0.1%

Low, common among large-caps

Healthcare 대형주 Median 0.8%

👤 Retail investors (estimated) 87.8%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

0.9%

Low — limited short-side pressure

Healthcare 대형주 Median 3.6%

Past 90 days Little change

Short interest days to cover

2.6 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 424.7M주

Float (tradable shares) 420.4M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding SNN

ETFs with the highest weightings · 10 total shown

MDEV

First Trust Indxx Medical Devices ETF

1.96%

$3M

PIEQ

Principal International Equity ETF

1.60%

$1.3B

SAGP

Strategas Global Policy Opportunities ETF

1.52%

$77M

TIIV

AAM Todd International Intrinsic Value ETF

1.27%

$32M

DTEC

ALPS Disruptive Technologies ETF

1.22%

$68M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당주 — 연 2.68% 배당

5년 배당 성장률 0.54%

Dividend Yield

2.68%

Industry average 1.25%

Dividend Per Share

$0.82

Annualized

Payout Ratio

52%

Share of net income paid as dividends

5-Year Growth

0.5%

Annualized dividend growth

📅 지급월 3월 · 10월

📊 총 이력 2000~2026 (53건)

연도별 배당 총액 추이

주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.

$0.63 +3.0%

2016

$0.62 -1.6%

2017

$0.73 +19.2%

2018

$0.73 -0.8%

2019

$0.75 +3.0%

2020

$0.75 +0.0%

2021

$0.75 +0.0%

2022

$0.75 +0.0%

2023

$0.75 +0.0%

2024

$0.76 +1.6%

2025

$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소

최근 배당 이력 총 53건

아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.

배당락일

주당 금액

지급일

당시 수익률

2026-03-27

$0.482

—

3.93%

2025-10-03

$0.300

—

2.89%

2025-03-28

$0.462

—

4.32%

2024-10-04

$0.288

—

3.46%

2024-04-01

$0.462

—

3.06%

2023-10-05

$0.288

—

3.19%

2023-03-30

$0.462

—

4.43%

2022-09-29

$0.288

—

4.54%

2022-03-31

$0.462

—

3.80%

2021-09-30

$0.288

—

3.02%

2021-04-05

$0.462

—

1.97%

2020-10-01

$0.288

—

2.62%

2020-04-02

$0.462

—

3.49%

2019-10-03

$0.288

—

2.18%

2019-04-04

$0.440

—

2.96%

2018-10-04

$0.280

—

2.71%

2018-04-05

$0.454

—

1.87%

2017-10-05

$0.246

—

2.36%

2017-03-29

$0.370

—

3.21%

2016-10-05

$0.246

—

2.66%

2016-04-20

$0.380

—

1.83%

2015-10-07

$0.236

—

2.40%

2015-04-15

$0.372

—

2.70%

2014-10-22

$0.220

—

1.79%

2014-04-17

$0.340

—

2.98%

2013-10-09

$0.208

—

3.02%

2013-04-17

$0.324

—

3.32%

2012-10-10

$0.198

—

2.61%

2012-04-18

$0.216

—

2.76%

2011-10-12

$0.132

—

2.46%

2011-04-29

$0.196

—

1.43%

2010-10-13

$0.120

—

2.32%

2010-04-21

$0.179

—

1.37%

2009-10-14

$0.109

—

2.17%

2009-04-15

$0.162

—

2.90%

2008-10-15

$0.099

—

1.89%

2008-04-16

$0.148

—

1.44%

2007-10-17

$0.090

—

1.24%

2007-04-18

$0.133

—

1.32%

2006-10-18

$0.082

—

1.49%

2006-04-19

$0.122

—

1.72%

2005-10-19

$0.075

—

1.58%

2005-04-20

$0.119

—

1.51%

2004-10-20

$0.068

—

1.05%

2004-04-21

$0.116

—

0.83%

2003-08-13

$0.060

—

1.79%

2003-04-17

$0.109

—

1.97%

2002-10-16

$0.063

—

1.72%

2002-04-17

$0.091

—

2.08%

2001-11-07

$0.056

—

1.77%

2001-04-18

$0.090

—

3.08%

2000-11-08

$0.055

—

2.22%

2000-05-04

$0.139

—

2.39%

* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.

💰 내가 100만원 투자한다면

연간 배당금 (세후) 2.3만원

5년 누적 (세후) 11.5만원

* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0.54% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
SNN This Stock	$12.9B	21.3 ▲	2.5 ▲	11.87% ▲	2.68% ▲	+2.7%
LLY	$1.13T	43.0 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.9%
JNJ	$634.1B	30.5 ▼	7.5 ▼	25.74% ▲	2.04% ▲	+1.6%
ABBV	$458.2B	127.9 ▼	-	15221.82% ▲	2.65% ▲	+0.9%
UNH	$382.1B	27.1 ▼	3.9 ▼	12.49% ▲	2.15% ▲	-0.7%
MRK	$323.7B	36.9 ▼	7.1 ▼	18.97% ▲	2.49% ▲	+0.5%
Sector Avg	-	25.8	2.7	-48.83%	1.25%	-

FAQ

What kind of company is 스미스 앤 네퓨(SNN)?

스미스 앤 네퓨(SNN) belongs to the Healthcare sector and operates in the Medical Devices industry.

What is the market cap of SNN?

The market cap of SNN is approximately $12.9B, ranking 806 within its sector.

Does SNN pay dividends?

SNN has a dividend yield of approximately 2.68%, with an annual dividend of $0.82.

What is the P/E ratio of SNN?

SNN has a P/E ratio of approximately 21.3x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for SNN?

SNN has recorded a 52-week high of $38.79 and a low of $28.56.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.